SCHEMBL29153231

SCHEMBL29153231

COc1ccc2ccc(=O)[nH]c2c1Cl

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 3/20 0.49
CA9 Q16790 3/20 0.49
NQO2 P16083 3/20 0.44
CYP19A1 P11511 2/20 0.44
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
MAPT P10636 2/20 0.40
KDM4E B2RXH2 1/20 0.40
S1PR4 O95977 1/20 0.40
HSP90AA1 P07900 1/20 0.40
G6PD P11413 1/20 0.40
S1PR1 P21453 1/20 0.40
MAPK1 P28482 1/20 0.40
OPRK1 P41145 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
CACNA1B Q00975 1/20 0.40
APBA1 Q02410 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22198968 0.77 NQO2 (0.43) NQO2CYP19A1KDM4EKMT2APDE3B
SCHEMBL1114643 0.76 CA12 (0.55) CA12CA9NQO2CYP19A1MAPT
SCHEMBL29153237 0.76 CA12 (0.53) CA12CA9MAPTLMNATP53
SCHEMBL25903828 0.75 CA12 (0.62) CA12CA9MAPTF11KMT2A
SCHEMBL22184948 0.74 ALDH1A1 (0.44) KDM4EMAPK1NPSR1TP53PDE3B
SCHEMBL17659906 0.74 TNF (0.53) CYP19A1MAPTKDM4ES1PR4HSP90AA1
SCHEMBL2796720 0.74 NQO2 (0.47) CA12CA9NQO2CYP19A1PDE4A
SCHEMBL29153226 0.74 NQO2 (0.46) CA12CA9NQO2CYP19A1PDE4A
SCHEMBL22185210 0.73 PDE3B (0.40) CA9PDE4APDE4BPDE4CPDE4D
SCHEMBL19713074 0.72 CA12 (0.50) CA12CA9NQO2CYP19A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327388-A1 QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2024-10-03 US disclosed
EP-4349831-A1 QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) 2024-04-10 EP disclosed
CN-117222639-A Quinoline amine compound, preparation method and medical application thereof 江苏恒瑞医药股份有限公司 2023-12-12 CN disclosed
WO-2022247920-A1 QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS 江苏恒瑞医药股份有限公司 2022-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327388-A1 QUINOLINAMINE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN PHARMACEUTICALS QARS1, THEM6, CYP4F11 CA12 4688/4885CA9 4552/4885NQO2 204/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.